Institutional Ownership
Nektar Therapeutics
CUSIP 640268306COM NEWNKTRQ1 2026
13D / 13G Filings
11
Schedule 13D/13G on record
Beneficial Filers
8
Distinct reporting persons
Largest Stake
11.1%
Max % of class reported
Institutional Holders
198
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
11 filings · latest Mar 6, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Mar 6, 2026 | Fmr LLC | 13G | 11.1% | 3.04M | SEC |
| 2 | Feb 13, 2026 | G1 Execution Services, LLC | 13G/A | 4.0% | 810.0K | SEC |
| 3 | Jan 30, 2026 | The Vanguard Group | 13G | 5.0% | 1.03M | SEC |
| 4 | Nov 14, 2025 | Nantahala Capital Management, LLC | 13G/A | 2.2% | 418.5K | SEC |
| 5 | Nov 13, 2025 | Susquehanna Portfolio Strategies, LLC | 13G | 6.3% | 1.24M | SEC |
| 6 | Oct 31, 2025 | The Vanguard Group | 13G/A | 5.0% | 948.6K | SEC |
| 7 | Oct 28, 2025 | Integrated Core Strategies (Us) LLC | 13G/A | 11.0% | 571.0K | SEC |
| 8 | Aug 14, 2025 | Nantahala Capital Management, LLC | 13G | 5.7% | 709.8K | SEC |
| 9 | Jul 18, 2025 | Blackrock, Inc. | 13G/A | 1.6% | 203.0K | SEC |
| 10 | Jul 9, 2025 | Biotechnology Value Fund L P | 13G | 7.4% | 1.28M | SEC |
1 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Nektar Therapeutics.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Fmr LLC | 4.30M | $309.61M |
| 2 | Bvf Inc/Il | 2.56M | $184.16M |
| 3 | Two Seas Capital LP | 1.96M | $140.96M |
| 4 | Two Sigma Investments, LP | 930.7K | $66.97M |
| 5 | Prosight Management, LP | 735.0K | $52.88M |
| 6 | Blackrock, Inc. | 692.6K | $49.84M |
| 7 | Morgan Stanley | 659.4K | $47.44M |
| 8 | Armistice Capital, LLC | 578.0K | $41.59M |
| 9 | Invesco Ltd. | 567.5K | $40.83M |
| 10 | Citadel Advisors LLC | 513.5K | $36.95M |